StreetAlpha.app
Home › Stocks › TNXP

Tonix Pharmaceuticals Holding Corp. (TNXP)

Healthcare
$2.38
▼ −6.67%
LAST CLOSE · NOV 20

Tonix Pharmaceuticals develops and sells prescription medicines for fibromyalgia and acute migraine. It last closed at $2.38 on Nov 20, down 6.67% on the day. The next earnings report for TNXP is expected around Tue, Feb 2, 2027. For the quarter ended Sep 2026, TNXP reported EPS of -$2.89 on revenue of $17.2M, with revenue up 423.8% from a year ago. Over its last 8 reports the stock moved an average of 3.1% the session after earnings. Over the last 12 months TNXP insiders bought $479K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is TNXP in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TNXP.

Key Stats

Last 12 months
Results
Revenue
$43.0M
+318.0% vs a year ago
Net income
−$181.0M
−420.4% margin
EPS (diluted)
−$12.39
−104.4% vs a year ago
Free cash flow
−$170.0M
−395.0% margin
Valuation
Market cap
$46.2M
19.4M shares
P/E
–
No P/E while losing money
Price to sales
1.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$162.8M
At Sep 30
Shareholder equity
$199.5M
Shares outstanding
19.4M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $7.8M$7.8MFY2023FY2024: $10.1M$10.1MFY2024FY2025: $13.1M$13.1MFY2025

From TNXP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Feb 2
Estimated date · Time not announced
Reported EPS
-$2.89
Quarter ended Sep 2026
Year ago EPS
-$3.59
Same quarter last year
Revenue
$17.2M
+423.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $289.57Dec '24Mar 2025: -$2.84Mar '25Jun 2025: -$3.86Jun '25Sep 2025: -$3.59Sep '25Dec 2025: -$4.15Dec '25Mar 2026: -$2.93Mar '26Jun 2026: -$2.44Jun '26Sep 2026: -$2.89Sep '26Latest -$2.89
Revenue by quarter
Dec 2024: $2.6MDec '24Mar 2025: $2.4MMar '25Jun 2025: $2.0MJun '25Sep 2025: $3.3MSep '25Dec 2025: $5.4MDec '25Mar 2026: $6.9MMar '26Jun 2026: $13.5MJun '26Sep 2026: $17.2MSep '26Latest $17.2M
How TNXP moved after its last 8 reports
Average move the session after a report ±3.1%
Oct 15, 2026Time not announced+0.3%
Aug 10, 2026Time not announced+4.7%
May 1, 2026After the close−4.2%
Mar 13, 2026Time not announced−1.3%
Feb 3, 2026Time not announced−0.3%
Oct 27, 2025Time not announced+4.4%
Jul 25, 2025After the close−4.9%
Apr 25, 2025After the close−4.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on TNXPStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on TNXP
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on TNXP

Technical Analysis

TNXP · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 75% below its 20 day and 183% below its 50 day average. It is 381% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 11), oversold. The nearest support is the 52 week low at $2.30, and the nearest resistance the Pivot at $2.44.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 17.1%/day
Key levels
$20.5652 week high+763.9%
$11.45200 day average+381.1%
$9.41100 day average+295.4%
$6.7250 day average+182.4%
$5.51Swing high (Oct 29)+131.5%
$4.1820 day average+75.6%
$2.57Pivot R1+8.0%
$2.44Pivot+2.5%
$2.38Last close
$2.3052 week low−3.4%
$2.24Pivot S1−5.9%
Indicators
RSI (14)10.56Oversold below 30Oversold
MACD-1.18Below its signal lineBearish
Stochastic1.8Near the bottom of its rangeOversold
ADX (14)71.3Strong downtrend
Williams %R-97.4Oversold below −80, overbought above −20Oversold
CCI (20)-124.9Oversold below −100, overbought above 100Oversold
Rate of change−49.8%Change over 10 sessionsBearish
ATR (14)$0.41Typical daily range, 17.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TNXP

What happened before

See how TNXP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for TNXPHow many large options trades hit TNXP, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

TNXP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲64 buying vs 42 selling
  • ▲Held by funds +3.7 pts
  • ▲Funds holding +10
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding113103+9.7%
In funds' top 1000–
Held by funds51.9%48.3%+3.7 pts
New / increased22 / 4228 / 49−16.9%
Reduced / sold out29 / 138 / 5+223.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TNXP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

TNXP Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$479K8 buys · 4 insiders
Sold$00 sales · 0 insiders
Cluster buy: 3 insiders bought $132K between Jun 8 and Jun 12.
2026-03 bought $286K2026-06 bought $132K2026-08 bought $40K2026-11 bought $20KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 11Seth LedermanCEOBuy5,000$4.05$20K
Aug 27Seth LedermanCEOBuy2,000$13.79$28K
Aug 20Richard H BaggerDirectorBuy1,000$12.60$13K
Jun 12Carolyn E. TaylorDirectorBuy1,415$10.55$15K
Jun 9Seth LedermanCEOBuy5,000$11.79$59K
Jun 8Richard Newcomb StillwellDirectorBuy5,000$11.65$58K
Every insider buy and sale for TNXP over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See TNXP insider trades →

From SEC Form 4 filings by TNXP's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TNXP is in one of them and how their past TNXP trades turned out.

TNXP in the AI portfolios
Loading…

TNXP News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TNXP in an article yet. Here's the latest on the wider market.

TNXP in the news

About Tonix Pharmaceuticals Holding

Tonix Pharmaceuticals is a biopharmaceutical company based in Berkeley Heights, New Jersey. It sells TONMYA, a sublingual medicine for fibromyalgia in adults that is designed for bedtime use, along with two prescription sumatriptan products for acute migraine. Its main customers are prescribers in rheumatology, primary care, pain management and neurology practices, reached through national wholesalers and specialty distributors. The company also develops treatments for central nervous system disorders, immunology, infectious diseases and rare diseases.

Headquarters
Berkeley Heights, NJ